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ABSTRACT 
Introduction: Optimal pain control post-pancreatoduodenectomy is a challenge. Epidural 
analgesia (EDA) is increasingly utilized despite inherent risks and unclear effects on outcomes. 
Methods: All pancreatoduodenectomies (PD) performed from 1/2013-12/2017 were included. 
Clinical parameters were obtained from retrospective review of a prospective clinical database, 
the ACS NSQIP prospective institutional database and medical record review. Chi-
Square/Fisher’s Exact and Independent-Samples t-Tests were used for univariable analyses; 
multivariable regression (MVR) was performed.  
Results: 671 consecutive PD from a single institution were included (429 EDA, 242 non-EDA). 
On univariable analysis, EDA patients experienced significantly less wound disruption (0.2% vs. 
2.1%), unplanned intubation (3.0% vs. 7.9%), pulmonary embolism (0.5% vs. 2.5%), 
mechanical-ventilation >48hrs (2.1% vs. 7.9%), septic shock (2.6% vs. 5.8%), and lower pain 
scores.  On MVR accounting for baseline group differences (gender, hypertension, pre-operative 
transfusion, labs, approach, pancreatic duct size), EDA was associated with less superficial 
wound infections (OR 0.34; CI 0.14-0.83; P=0.017), unplanned intubations (OR 0.36; CI 0.14-
0.88; P=0.024), mechanical ventilation >48 hrs (OR 0.22; CI 0.08-0.62; P=0.004), and septic 
shock (OR 0.39; CI 0.15-1.00; P=0.050). EDA improved pain scores post-PD days 1-3 
(P<0.001). No differences were seen in cardiac or renal complications; pancreatic fistula (B+C) 
or delayed gastric emptying; 30/90-day mortality; length of stay, readmission, discharge 
destination, or unplanned reoperation. 
Conclusion: Based on the largest single institution series published to date, our data support the 
use of EDA for optimization of pain control. More importantly, our data document that EDA 
significantly improved infectious and pulmonary complications. 
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INTRODUCTION 
 The number of pancreatic resections in total and for benign pancreatic disease has 
steadily increased over the preceding decades.(1, 2) Despite this increasing incidence, the 
morbidity of pancreatic surgery, pancreatoduodenectomy (PD) in particular, has persisted around 
45-50%.(3, 4) The development and implementation of Enhanced Recovery After Surgery 
(ERAS) programs serves as one strategy to try and mitigate such morbidity, by addressing 
postoperative stress and pain control, and through promotion of early oral feeding and 
mobility.(5) While ERAS programs have been established for nearly two decades in other 
surgical subspecialties, only recently has hepatopancreatobiliary (HPB) surgery adopted the 
concept.(6) 
 A key component to existing HPB-specific ERAS protocols is the use of regional 
analgesia, most commonly thoracic epidural-delivered analgesia. However, these guidelines are 
largely based on existing literature supporting the use of epidural analgesia (EDA) in non-HPB-
specific patient populations. There is a large body of evidence to show that post-operative pain 
control is improved with EDA over other modalities across surgical subspecialties.(7-20) 
However, the association between EDA and reduced post-operative morbidity is less clear.  A 
myriad of studies have shown reduction in mortality, infectious, pulmonary, renal, 
gastrointestinal, or cardiovascular complications with the use of EDA: but these results are based 
on heterogeneous cohorts ranging in breadth from inclusion of all surgical patients to highly 
specialized subpopulations for specific procedures.(7-9, 11, 12, 14, 15, 18, 20-31) Meanwhile, 
others have found conflicting results to suggest no benefit or worse outcomes with the use of 
EDA.(32-34) These differences in outcomes based on such diverse study populations suggests 
the true effect of EDA may vary by procedure type.(9)  While several prospective studies exist 
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regarding the use of EDA in abdominal surgery, few are HPB- or pancreatectomy-specific.(35-
37)  
 Far fewer studies have been dedicated to examining outcomes after pancreatectomy, 
particularly PD, and results are again mixed. Most agree that postoperative pain control after PD 
is improved with EDA(38-41) but argue that the rate of epidural failure is not worth this 
benefit.(38, 41) While there is some evidence to suggest improved postoperative outcomes with 
the use of EDA,(40, 42) others have reported the contrary.(38, 39) Many of these studies are 
restricted by very small numbers of patients, or are comprised of large datasets like the National 
Inpatient Sample with their unique and well-established set of limitations. Thus, larger single- or 
multi-institutional studies for the PD-specific population are warranted to further our knowledge 
of the effects of EDA on this specialized group of patients. 
  In this study, we aimed to perform the largest single-institution evaluation of post-
operative outcomes for those with and without EDA after PD. A secondary aim was assessment 
of postoperative pain control in the EDA versus non-EDA subgroups, as pain control may have a 
direct link to certain postoperative outcomes as well as patient satisfaction and participation in 
rehabilitation. 
METHODS 
Patient Population 
 A retrospective review of our institution’s prospectively maintained American College of 
Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP) database was 
performed to gather all recorded pancreatoduodenectomies (PD) performed from 1/2013-
12/2017 (5-year period). The electronic medical record of each patient was reviewed to enhance 
existing data and to determine the analgesia modality utilized post-PD. Those with an epidural 
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(opioid and/or local anesthetic) placed in the immediate perioperative period were assigned to 
the Epidural Analgesia (EDA) group, whereas those without an epidural placed were assigned to 
the Non-Epidural Analgesia (Non-EDA) group. All postoperative pain scores for the first 72 
hours after the time of case completion were reviewed and recorded. Acute Pain Service, General 
Surgery, and nursing notes were reviewed for immediate post-operative EDA complications 
(including hypotension, somnolence, dislodgment, etc.) and mitigation strategies that were 
employed. All data were collected and recorded according to the Indiana University Institutional 
Review Board guidelines. 
Statistical Analysis 
 Univariable analysis was performed to compare EDA and Non-EDA subgroups at 
baseline, as well as postoperative outcomes. Chi-Square/Fisher’s Exact test and the Independent-
Samples t-test were used for categorical and continuous data respectively. To account for 
differences in the EDA and Non-EDA subgroups, multivariable analyses were performed using 
binary logistic and linear regression for categorical and continuous postoperative outcomes 
respectively. SPSS, Version 24 (IBM corp.) and SAS software were used for these analyses. 
Variable Definitions  
 Several variables were included outside of the standard ACS-NSQIP database, or were 
redefined as follows: 
1) Chronic Pancreatitis: patients were considered to have a primary indication for surgery of 
“Chronic Pancreatitis” when this was the primary indication for surgery listed in the 
operative report 
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2) Opioid User: patients were considered to be “Opioid Users” if opioids were prescribed 
and taken preoperatively for at least 1 week prior to surgery, based on the electronic 
medical record 
3) Wound Classification: through thorough review of the operative reports and 
intraoperative cultures, only individuals with obvious purulence, purulent fluid or + fluid 
cultures, infected necrosis with documented + cultures, or gross contamination of 
gastrointestinal contents intraoperatively were included in the “Dirty/Infected” category. 
All other patients were grouped as “Other” which encompasses the standard 
Clean/Contaminated cases, as well as non-infectious Contaminated cases (ex: 
inflammatory changes, the presence alone of a biliary stent in the absence of purulent bile 
and + cultures).    
4) Pathology Classification: patients were grouped into a Malignant or Benign/Non-
Neoplastic pathology category based on individual diagnoses detailed in the Results 
section.  
5) Clinically Significant Pancreatic Fistula: Included those graded B or C according to the 
International Study Group on Pancreatic Surgery(43) 
6) Pain Scores: as reported by nursing at regular intervals (approximately every 1-4 hours 
depending on acuity of care), graded on a 0-10 scale by the patient 
Perioperative Care 
 All PD were performed by surgeons well versed in the operation who regularly perform 
complex hepatobiliary operations. Over 95% of the PD performed in this series were by surgeons 
who completed over 100 PD throughout the 5-year period. The decision to pursue EDA or Non-
EDA was dependent on the presence/absence of standard contraindications (i.e. infection at 
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insertion site, impaired coagulation)(20) patient and surgeon preference. Pain control for those 
with EDA is managed entirely by a specialized service of anesthesiologists, the Acute Pain 
Service until the time of epidural catheter removal. Patients without EDA are managed entirely 
by the surgical service.  
RESULTS 
Study Population  
A total of 671 patients underwent PD over the 5-year period (January 2013-December 
2017). For 429 (63.9%) patients, pain was controlled with EDA with or without alternative 
means, whereas pain was controlled with alternate methods only (non-EDA) for the other 242 
(36.1%) patients. Though patients underwent PD for a wide variety of pathologies, there was a 
similar distribution of malignant pathology for EDA (n=281, 65.5%) and non-EDA (n=164, 
67.8%) patients (P=0.551). The most common indication for PD was primary pancreatic 
malignancy, including ductal adenocarcinoma/acinar cell carcinoma (n=308, 45.9%). For benign 
pathology, the most frequent was chronic pancreatitis (n=104, 46.0%) which was equally 
distributed between EDA and non-EDA patients (15.6% vs 15.3%, P=1.000). The distribution of 
malignant and benign pathologies are summarized in Figure 1a and Figure 1b respectively. 
Baseline demographics and comorbidities were similar with the exception of a higher 
proportion of males (57.4% vs. 46.4%, P=0.006), history of hypertension (61.2% vs. 51.0%, 
P=0.012), and preoperative transfusion requirements (2.5% vs. 0.2%, P=0.010) in non-EDA 
patients compared to EDA patients. There was a higher proportion of open PD performed (99.5% 
vs. 96.7%, P=0.006), and a higher incidence of small main pancreatic ducts defined as <3mm 
(21.5% vs. 13.8%, P=0.017) in the EDA group. These and other baseline features are 
summarized in Table 1.   
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Postoperative Outcomes 
 Patients with EDA revealed several significantly improved infectious, wound, and 
pulmonary outcomes above non-EDA patients on univariable and multivariable regression 
analyses. On univariable analysis, those with EDA had lower rates of septic shock (2.6% vs. 
5.8%, P=0.034), wound disruption (0.2% vs. 2.1%, P=0.025), unplanned intubation (3.0% vs. 
7.9%, P=0.005), prolonged ventilation (2.1% vs. 7.9%, P<0.001), and pulmonary embolism 
(0.5% vs. 2.5%, P=0.029). After multivariable regression controlling for significant group 
differences, several infectious and pulmonary outcomes were still improved with EDA.  Namely, 
those with EDA were less likely to experience superficial wound infections (OR 0.34 [0.14-
0.83], P=0.017), septic shock (OR 0.39 [0.15-1.00], P=0.050), unplanned intubation (OR 0.36 
[0.14-088], P=0.024), and prolonged ventilation (OR 0.22 [0.08-0.62], P=0.004).  
 There was no significant difference in the rate of renal or cardiovascular complications, 
clinically significant postoperative pancreatic fistula (B+C) or delayed gastric emptying or length 
of stay between groups. The 30- and 90-day mortality, 30-day readmission rate, and incidence of 
unexpected return to the operating room within 30-days was also similar between patients with 
and without EDA. Outcomes are summarized in Table 2. 
Pain Score Assessment 
 Postoperative pain scores were compared between EDA and non-EDA patients for the 
first 72-hours postoperatively at 24-hour intervals.  On univariable analysis, postoperative pain 
scores were significantly lower for those with EDA compared to those without EDA on post-
operative day (POD) 1, POD2, POD3, and on average over all 3 days. (Figure 2). On 
multivariable regression analysis, average pain scores remained significantly lower for those 
with EDA compared to those without EDA on POD 1 (B-coefficient -1.01[-1.42 to -.589]), POD 
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2 (B-coefficient -0.73[-1.09 to -0.36]), POD 3 (B-coefficient -0.79[-1.16 to -0.41]), and 
aggregate POD 1-3 (B-coefficient -0.91[-1.25 to -0.56]) (all P<0.001).  
Epidural Complications 
 Complaints or complications potentially related to EDA were recorded for the first 24 
hours postoperatively. One hundred and thirty-three of the 429 (31.0%) with an epidural had one 
or more issues within the first 24 hours. The most common occurrence was hypotension 
with/without somnolence or respiratory depression (n=68, 51.1%). Symptoms of opioid toxicity 
alone (somnolence, respiratory depression) were next most common (n=33, 24.8%), with the 
remaining patients experiencing a number of more rare complications. (Figure 3a)  In general, 
these issues were mitigated with only minor adjustments necessary to the rate of infusion (n=50, 
37.6%), medication mixture (n=55, 41.3%), or a combination of these two strategies (n=6, 
4.5%).  Only 18 patients (13.5%) required removal or replacement of the catheter for inadequate 
pain control secondary to suboptimal placement or accidental dislodgment. (Figure 3b) 
DISCUSSION 
 ERAS programs for HPB surgery have recently been developed and implemented in an 
attempt to improve the seemingly stagnant and high rate of morbidity after pancreatic surgery. 
One important feature is the use of EDA to not only improve pain control, but surgical outcomes 
as well.  However, pancreatectomy-specific literature is limited to very small series or large 
national databases with inherent limitations. To our knowledge, this is the largest single-
institution series to date (671 patients) examining primarily surgical outcomes after PD with and 
without the use of EDA. While not the focus of the study, pain control was assessed as a 
secondary initiative.   
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 In the present study, we report a lower rate of certain infectious complications with the 
use of EDA. Specifically, there was a lower unadjusted rate of septic shock for patients receiving 
EDA compared to non-EDA patients, which was borderline significant on multivariable 
regression analysis (P=0.050). We also found a significantly lower rate of superficial surgical 
site infections for patients with EDA after controlling for potential confounders. Notably, our 
institutional superficial surgical site infection rate for the entire cohort (3.3%) was much lower 
than expected for a clean-contaminated operation (exceeding 10%); this already low rate was 
further enhanced by the use of EDA. Results in the literature regarding infectious outcomes and 
EDA are conflicting and difficult to interpret due to differences in definitions for infectious 
complications. The majority of existing studies report decreased or similar rates of infectious 
complications including rates of pneumonia, urinary tract infection, sepsis/bacteremia, wound 
infection, or aggregates of these individual outcomes.(8, 9, 19, 24, 29, 39, 44-46) In examining 
liver and pancreatic resections specifically, Amini et al. revealed a lower rate of postoperative 
sepsis, but similar rate of wound infections between EDA and non-EDA patients.(45) In contrast, 
Pratt et al. examined PD specifically, and found an increased rate of aggregate infectious 
complications with EDA use. However, there was no significant difference in the rate of any 
individual component included in this aggregate analysis, including sepsis or wound 
infection.(38) Another study examining PD alone revealed a higher rate of overall wound 
complications with the use of EDA, defined as internal or external disruption; it is unclear if this 
definition includes wound infections, making comparison to the present study results 
difficult.(42) Mechanistically, there is support in the literature for a reduced rate of infectious 
complications with the use of EDA through dampening of the stress response to surgery and its 
associated attenuation of the immune system.(14, 23, 24) Thus, there is a logical explanation and 
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some prior evidence to validate our reduced rate of sepsis with EDA use, but our finding of 
reduced superficial wound infection in the EDA group is to our knowledge previously 
unreported for this population and warrants further evaluation.  
 Pulmonary complications are another heterogeneous category of morbidity cited in the 
EDA literature. It is known that upper abdominal surgery may have adverse effects on 
pulmonary function. In general, existing literature supports the claim that EDA reduces the rate 
of pulmonary complications, including respiratory failure, prolonged ventilation, and respiratory 
depression.(8, 9, 12, 15, 21, 22, 25, 31, 40, 45, 46) Though the minority, two studies regarding 
PD specifically have shown equal(39) or even increased(38) rates of pulmonary complications 
with EDA. Our results agree with the majority of the literature, as we found the rate of prolonged 
ventilation (>48 hours) and unplanned intubation was significantly lower in the EDA group 
compared to patients with non-EDA. Moraca et al. and Liu et al. propose this improvement in 
pulmonary function with the use of EDA is not only related to superior pain control, but also 
improvement in chest wall compliance, and modulation of inappropriate diaphragmatic reflex 
inhibition.(14, 23)   
 Many outcomes in the present study are in line with the existing PD-specific literature, 
including similar postoperative length of stay, mortality, readmission rates, and rate of delayed 
gastric emptying,(38, 39) yet some discrepancies remain. Pratt et al. reported a higher rate of 
POPF with the use of EDA that did not hold true in the present study.(38) Amini et al. reported a 
shorter postoperative length of stay in the EDA group on multivariable regression analysis, 
whereas we found this to be similar between EDA and non-EDA patients.(42) 
 The most consistently reported benefit of EDA over alternative means is superior pain 
control in the immediate postoperative period. While the existing literature for the surgical 
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population in general is expansive, studies pertaining to PD are fairly limited. Nonetheless, PD-
specific studies that do address postoperative pain control are generally in agreement: EDA 
provides a postoperative analgesic benefit over other conventional methods of pain control. (38-
40) Though not the primary aim of our study, we did include this metric in our analysis and 
validated these prior findings. In the present study, patients with EDA had significantly lower 
pain scores on POD1-3 compared to patients without EDA.  
 Despite the potential benefits, EDA holds inherent risk that cannot be ignored. These 
potential complications include sympathetic blockade resulting in hypotension, systemic opioid 
absorption with respiratory depression or somnolence/confusion, nausea/vomiting, pruritis, 
urinary retention, or the highly feared but exceedingly rare epidural hematoma or abscess that 
may cause permanent neurologic injury.(14, 18, 20, 40, 47) We examined the immediate (first 
24-hours postoperatively) potential adverse effects associated with EDA in our patient 
population, and largely found relatively minor complications that were addressed with minimal 
changes in management. Most patients (69%) had no immediate complication associated with 
EDA. Because EDA requires close monitoring for complications and expertise in quickly 
mitigating such issues, Davies et al. supports the use of an Acute Pain Service—a group of 
specialized anesthesiologists familiar with EDA—to manage this modality of postoperative 
analgesia.(20) At our institution, this recommendation is followed.  
 This study has a few limitations. The first is in regard to the retrospective review of 
particular data points, namely those involving the use of EDA, immediate complications of EDA, 
and postoperative pain scores. We did our best to minimize missing retrospective data through a 
thorough review of the medical record, including nursing documentation of postoperative 
complications associated with the epidural and notification of house-staff. Secondly, the range of 
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EDA use was from 1-6 days (mean 3.6 days) in our patient cohort. Pain scores were tracked only 
through POD 3, to match with this average length of time the epidural catheter was in place. 
Though some patients had accidental dislodgment or required early removal of the epidural 
catheter before POD 3, this was the minority of cases (37 of 429 patients, 8.6%). Thus, we 
believe any skew in pain scores, or overall surgical outcomes, resulting from individuals utilizing 
EDA less than 3 days is minimal. Finally, the decision to utilize EDA at our institution is based 
partly on physician and patient preference, and may serve as a source of unaccountable selection 
bias. We tried to reduce this effect through controlling for all other recognized baseline group 
differences in multivariable analysis that may affect postoperative outcomes. 
CONCLUSION 
The use of EDA after pancreatoduodenectomy not only improved postoperative pain control, but 
reduced the rate of certain infectious and pulmonary complications. With proper patient selection 
and in the hands of experienced Acute Pain specialists, the use of EDA appears to be safe. The 
high rate of EDA use at our institution, as well as EDA recommendations included in the HPB-
specific Enhanced Recovery protocols are justified. 
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Table 1 Comparison of Baseline and Perioperative Characteristics for Patients with and without 
Epidural Analgesia 
Characteristic 
Epidural analgesia 
(N=429) 
Non-epidural 
analgesia (N=242) p Value 
Data Missing,N Data Missing, N 
Preoperative demographic and 
comorbidity 
Age, y, mean (SD) 
64.0 
(12.9) 0 
63.6 
(12.4) 0 0.667 
Sex, male, n (%) 
199 
(46.4) 0 
139 
(57.4) 0 0.006* 
Race, Caucasian, n (%) 
403 
(94.2) 1 
224 
(94.1) 4 0.983 
Preoperative opioid use, n (%) 
176 
(41.0) 0 
99 
(40.9) 0 0.976 
BMI, kg/m², mean (SD) 
27.5 
(5.8) 0 
27.6 
(6.1) 0 0.721 
Diabetes, n (%) 
107 
(24.9) 0 
74 
(30.6) 0 0.114 
Tobacco use, n (%) 
121 
(28.2) 0 
81 
(33.5) 0 0.153 
COPD, n (%) 34 (7.9) 0 22 (9.1) 0 0.600 
CHF, n (%) 2 (0.5) 0 1 (0.4) 0 1.000 
HTN, n (%) 
219 
(51.0) 0 
148 
(61.2) 0 0.012* 
Steroid/immunesuppression, n 
(%) 9 (2.1) 0 5 (2.1) 0 0.978 
Weight loss (>10% in 6 
months), n (%) 91 (21) 0 
53 
(21.9) 0 0.779 
Preoperative transfusion, n (%) 1 (0.2) 0 6 (2.5) 0 0.010* 
SIRS/sepsis, n (%) 1 (0.2) 0 2 (0.8) 0 0.296 
ASA Class, mean (SD) 
3.0 
(0.2) 0 
3.0 
(0.3) 0 0.552 
Preoperative lab & pancreas-
specific feature 
BUN, mg/dL, mean (SD) 
15.8 
(7.3) 3 
15.7 
(7.8) 8 0.862 
Creatinine, mg/dL, mean (SD) 
0.9 
(0.3) 3 
0.9 
(0.4) 8 0.955 
Albumin, g/dL, mean (SD) 
3.9 
(0.5) 5 
3.7 
(0.6) 12 <0.001* 
White Cell Count (µL¯ ¹), mean 8.0 7 8.0 14 0.968 
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(SD) (3.1) (3.8) 
Hematocrit, g/dL, mean (SD) 
38.3 
(5.1) 8 
36.8 
(6.1) 13 0.003* 
INR, mean (SD) 
1.1 
(0.1) 48 
1.1 
(0.2) 48 0.009* 
Preoperative jaundice, n (%) 
160 
(37.3) 0 
82 
(33.9) 0 0.377 
Preoperative biliary stenting, n 
(%) 
227 
(52.9) 0 
135 
(55.8) 0 0.474 
Preoperative chemotherapy, n 
(%) 
61 
(14.2) 0 
38 
(15.7) 0 0.603 
Preoperative radiation, n (%) 11 (2.6) 0 8 (3.3) 0 0.578 
Malignant pathology, n (%) 
281 
(65.5) 0 
164 
(67.8) 0 0.551 
Primary diagnosis of 
pancreatitis, n (%) 
62 
(14.5) 0 
29 
(12.0) 0 0.370 
Perioperative feature 
Wound class (Dirty/Infected) 8 (1.9) 0 6 (2.5) 0 0.593 
Duration of operation, minutes, 
mean (SD) 
292.4 
(90.9) 0 
297.0 
(102.4) 0 0.562 
Open operative approach, n (%) 
427 
(99.5) 0 
234 
(96.7) 0 0.006* 
Small duct (< 3mm) , n (%) 
88 
(21.5) 19 
32 
(13.8) 10 0.017* 
Soft gland, n (%) 
178 
(43.7) 22 
100 
(43.7) 13 0.987 
Vascular reconstruction 
performed, n (%) 
43 
(10.0) 0 
31 
(12.8) 0 0.268 
*Significant 
CHF, congestive heart failure; HTN, hypertension; SIRS, Systemic Inflammatory Response 
Syndrome; ASA, American Society of Anesthesiologists; BUN, blood urea nitrogen; INR 
International Normalized Ratio 
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Table 2 Summary of Postoperative Outcomes for Patients with and without Epidural Analgesia 
Outcome 
Epidural 
analgesia 
(N=429) 
Non-
epidural 
analgesia 
(N=242) 
Univariable 
analysis Multivariable analysis* 
p Value p Value 
B-Coefficient or 
odds ratio [95% 
CI] 
Wound/infectious outcome, n 
(%) 
Superficial surgical 
infection 10 (2.3) 12 (5.0) 0.066 0.017† 0.34 [0.14-0.83] 
Deep surgical infection 5 (1.2) 5 (2.1) 0.508 0.363 0.53 [0.14-2.08] 
Organ space infection 33 (7.7) 27 (11.2) 0.131 0.287 0.71 [0.38-1.33] 
Pneumonia 10 (2.3) 12 (5.0) 0.066 0.299 0.56 [0.19-1.70] 
Urinary tract infection 11 (2.6) 9 (3.7) 0.398 0.555 0.71 [0.23-2.21] 
C.Diff infection 5 (1.3) 2 (1.2) 1.000 0.524 1.80 [0.29-11.05] 
Sepsis 17 (4.0) 18 (7.4) 0.052 0.066 0.47 [0.21-1.05] 
Septic shock 11 (2.6) 14 (5.8) 0.034† 0.050† 0.39 [0.15-1.00] 
Wound disruption 1 (0.2) 5 (2.1) 0.025† 0.071 0.13 [0.01-1.19] 
Pulmonary outcome, n (%) 
Unplanned intubation 13 (3.0) 19 (7.9) 0.005† 0.024† 0.36 [0.14-0.88] 
Pulmonary embolism 2 (0.5) 6 (2.5) 0.029† 0.107 0.15 [0.02-1.50] 
Vent >48 hours 9 (2.1) 19 (7.9) <0.001† 0.004† 0.22 [0.08-0.62] 
Renal outcome, n (%) 
Progressive renal 
insufficiency 0 (0.0) 1 (0.4) 0.361  0.293 0.18 [0.01-4.36]  
Acute renal failure 4 (0.9) 5 (2.1) 0.296 0.533 0.64 [0.15-2.65] 
Cardiovascular outcome, n 
(%) 
Cerebrovascular accident 2 (0.5) 1 (0.4) 1.000 0.285 5.43 [0.01-107.67] 
Cardiac arrest 4 (0.9) 3 (1.2) 0.707 0.664 1.77 [0.14-22.90] 
Myocardial infarction 6 (1.4) 3 (1.2) 1.000 0.723 1.43 [0.20-10.21] 
Transfusion w/in 72 hrs 
postop 113 (26.3) 65 (26.9) 0.884 0.157 1.39 [0.88-2.20] 
Deep venous thrombosus 11 (2.6) 8 (3.3) 0.578 0.573 1.38 [0.44-4.40] 
Pancreatectomy-specific 
outcome, n (%)      
Pancreatic fistula (B or C) 33 (7.7) 24 (9.9) 0.321 0.504 0.79 [0.40-1.58] 
Delayed gastric emptying 72 (16.8) 40 (16.5) 0.932 0.684 0.90 [0.54-1.51] 
Quality outcome 
Length of hospital stay, d, 
mean (SD) 10.5 (10.8) 11.1 (9.5) 0.460 0.776  -0.29 [-2.3 - 1.69] 
Discharge to home, n (%) 358 (84.2) 187 (79.2) 0.106 0.341 0.78 [0.47-1.30] 
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30-day mortality, n (%) 10 (2.3) 5 (2.1) 0.824 0.493 1.59 [0.43-5.92] 
90-day mortality, n (%) 10 (2.3) 7 (2.9) 0.657 0.928 0.95 [0.30-3.0] 
≥ 1 readmission, n (%) 48 (13.5) 35 (14.5) 0.734 0.972 0.99 [0.58-1.69] 
≥ 1 return to OR, n (%) 11 (2.6) 10 (4.1) 0.263 0.293 0.59 [0.22-1.58] 
*Multivariable model included male sex, hypertension, preoperative transfusion, albumin, 
hematocrit, INR, operative approach, small duct 
†
 Significant 
OR, operating room 
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FIGURE LEGENDS 
Figure 1. (A) Distribution of Malignant Pathology Amongst Pancreatoduodenectomy Cohort 
(B) Distribution of Benign Pathology Amongst Pancreatoduodenectomy Cohort 
Figure 2. Univariable Analysis of Pain Scores (Postoperative Days 1-3 and Aggregate) for 
Patients With and Without Epidural Analgesia (Mean±Standard Deviation) 
Figure 3. (A) Distribution of Potential Epidural Complications Within 24-Hours Postoperatively. 
*Other includes Nausea (2), Dizziness (1), Need for Anticoagulation (1), oncern for 
Medication-Related Heart Block (1), and Unstated Reason for Epidural Adjustment (4) 
(B) Distribution of Mitigation Strategies for Potential Epidural Complications Within 24-Hours 
Postoperatively 
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PRECIS 
The use of epidural analgesia (EDA) after pancreatoduodenectomy not only improved 
postoperative pain control but also reduced the rate of certain infectious and pulmonary 
complications in this series. The recommendation for EDA use in hepatopancreatobiliary-
specific enhanced recovery protocols may be justified. 
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